Browsing by Author Qin, Albert

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 7 of 7
TitleAuthor(s)Issue Date
 
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
Journal:Annals of Hematology
Abu-Zeinah, GhaithQin, AlbertGill, HarinderKomatsu, NorioMascarenhas, JohnShih, Weichung JoeZagrijtschuk, OlehSato, ToshiakiShimoda, KazuyaSilver, Richard T.Mesa, Ruben
15-Aug-2024
 
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms
Journal:Current Hematologic Malignancy Reports
Bose, PrithvirajXiao, ZhijianHasselbalch, Hans C.Prchal, Josef T.Duan, MinghuiYacoub, AbdulraheemRampal, RaajitKiladjian, Jean-JacquesHobbs, Gabriela S.Tashi, TsewangShimoda, KazuyaKirito, KeitaGill, HarinderHou, Hsin-AnLee, Sung-EunHuang, JianLi, BingQin, AlbertYu, Lennex Hsueh-LinMascarenhas, John O.Mesa, Ruben A.
12-Jul-2025
 
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
Journal:Clinical Lymphoma, Myeloma and Leukemia
Masarova, LuciaKomatsu, NorioGill, HarinderJin, JieLee, Sung-EunHou, Hsin-AnSato, ToshiakiQin, AlbertUrbanski, RaymondShih, WeichungZagrijtschuk, OlehZimmerman, CraigMesa, Ruben
1-Sep-2023
 
Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera
Journal:Blood
Yacoub, AbdulraheemAbu-Zeinah, GhaithQin, AlbertShih, Weichung JoeDa'na, WaleedTashi, TsewangZagrijtschuk, OlehGeller, RobertGill Harinder
5-Nov-2024
 
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
Journal:Annals of Hematology
Yacoub, AbdulraheemAbu-Zeinah, GhaithQin, AlbertTashi, TsewangDa’na, WaleedShih, Weichung JoeZagrijtschuk, OlehTsai, Chan-YenGeller, RobertKomatsu, NorioMesa, RubenSingh, Gill Harinder
13-Jan-2025
 
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
Journal:The Lancet Haematology
Mesa, RubenGill, HarinderZhang, LeiJin, JieKirito, KeitaKomatsu, NorioQin, AlbertXiao, ZhijianTashi, TsewangShimoda, KazuyaOhishi, KohshiChen, SuningZuo, XuelanShirane, ShuichiHu, YuZhang, SujiangWang, YiTakenaka, KatsutoIchii, MichikoXu, NaShih, Lee-YungLim, Ken-HongLee, Sung-EunBae, Sung HwaTeo, Winnie Z YMaze, DawnOh, Stephen TBose, PrithvirajSato, ToshiakiZagrijtschuk, OlehLin, SheenaShih, Weichung JoeMascarenhas, JohnMasarova, Lucia
1-Nov-2025
 
Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial
Journal:Journal of Clinical Oncology
Mesa, Ruben AGill, HarinderXiao, ZhijianKomatsu, NorioQin, AlbertTashi, TsewangZhang, LeiJin, JieKirito, KeitaOhishi, KohshiShirane, ShuichiShih, Lee-YungLee, Sung-EunTeo, Winnie ZYMaze, DawnOh, StephenSato, ToshiakiShih, WeichungMascarenhas, JohnMasarova, LuciaSURPASS-ET Study Group
1-Jun-2025
Showing results 1 to 7 of 7